Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Geriatrics | Gynecology | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Oncology | Orthopedics | Pharmacy | Pulmonology | Surgery | Anesthesiology & Pain | Conference News

Back to Journal Articles

Idarucizumab Shows Reliable Reversal of Dabigatran

Last Updated: July 13, 2017.

Idarucizumab can reverse the anticoagulant effect of dabigatran in emergency situations, according to a study published online July 11 in the New England Journal of Medicine. The research was published to coincide with the International Society on Thrombosis and Haemostasis Congress, held from July 8 to 13 in Berlin.

THURSDAY, July 13, 2017 (HealthDay News) -- Idarucizumab can reverse the anticoagulant effect of dabigatran in emergency situations, according to a study published online July 11 in the New England Journal of Medicine. The research was published to coincide with the International Society on Thrombosis and Haemostasis Congress, held from July 8 to 13 in Berlin.

Charles V. Pollack Jr., M.D., from Thomas Jefferson University in Philadelphia, and colleagues performed a multicenter open-label study to examine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in 503 patients with uncontrolled bleeding (group A, 301 patients) or who were about to undergo an urgent procedure (group B, 202 patients).

The researchers found that 45.5 and 32.6 percent of patients in group A presented with gastrointestinal bleeding and intracranial hemorrhage; the median time to bleeding cessation was 2.5 hours. The median time to initiation of the intended procedure was 1.6 hours in group B; in 93.4, 5.1, and 1.5 percent of patients, periprocedural hemostasis was assessed as normal, mildly abnormal, and moderately abnormal, respectively. At 90 days, thrombotic events occurred in 6.3 and 7.4 percent of patients in groups A and B, respectively, and the corresponding mortality rates were 18.8 and 18.9 percent. No serious adverse safety signals were observed.

"In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran," the authors write.

The study was funded by Boehringer Ingelheim, the manufacturer of idarucizumab.

Abstract
Full Text
More Information


Previous: Western Diet Associated With Chronic Hepatic Inflammation Next: Potential First U.S. Gene Therapy Now Under FDA Review

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: